Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

@article{Cummings1998EffectOA,
  title={Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.},
  author={Steven R. Cummings and Dennis M. Black and Desmond E Thompson and William B. Applegate and Elizabeth Barrett-Connor and Thomas A. Musliner and Lisa Palermo and Ronald Prineas and Susan M. Rubin and J C Scott and Thomas M. Vogt and Robert B. Wallace and A. John Yates and Andrea Z. LaCroix},
  journal={JAMA},
  year={1998},
  volume={280 24},
  pages={
          2077-82
        }
}
CONTEXT Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures. [...] Key MethodDESIGN Randomized, blinded, placebo-controlled trial. SETTING Eleven community-based clinical research centers. Expand
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.
TLDR
In women with low bone mass who do not meet the bone mineral density criterion for osteoporosis, alendronate is effective in reducing the risk of vertebral fractures.
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
TLDR
Reductions in fracture risk during treatment with alendronate are consistent in women with existing vertebral fractures and those without such fractures but with bone mineral density in the osteoporotic range.
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial
TLDR
Among patients who adhere to treatment with alendronate, even those who lose BMD benefit from a substantial reduction in risk of vertebral fracture, and the reduction in bone turnover induced by alendronsate might be more important than BMD changes.
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
TLDR
Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture, and these results highlight the consistent antifracture efficacy of denosumAB in patients with varying degrees of fracture risk.
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
TLDR
Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures, suggesting that, among women taking antiresorptive agents, greater increases in B MD are associated with lower risk of new fractures.
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial
  • A. Schwartz, D. Bauer, +8 authors D. Black
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2010
TLDR
Continuing ALN for 10 years instead of stopping after 5 years reduces NVF risk in women without prevalent vertebral fracture but does not reduce risk of NVF in women whose T‐scores are greater than −2.5 or less.
Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women
TLDR
Risedronate treatment significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women.
BACKGROUND Increased dietary calcium intake has been proposed as a population-based public health intervention to prevent osteoporotic fractures. We have examined whether calcium supplementation
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
TLDR
There was insufficient power to compare the fracture risks between alendronate and raloxifene, and the only adverse events with an incidence that differed between groups were colonoscopy, diarrhea, and nausea.
Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis
TLDR
Overall results of limited studies for non-bisphosphonate drugs showed increased BMD and raloxifene significantly decreases the risk of subsequent clinical vertebral fractures, reducing their incidence and improving BMD in postmenopausal women with osteopenia or osteoporosis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
TLDR
Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function: A Prospective Study
TLDR
This study examined the effect of incident vertebral fractures on back pain and back-related functional limitations in a large community-based sample of elderly women who underwent serial spinal radiography and annual assessments of backPain and disability over the same period.
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.
Background Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.
TLDR
A residual decrease in bone turnover may be found up to 2 years after discontinuation of alendronate, and continuous therapy with alendronsate is required to achieve a continuous gain in BMD.
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial
TLDR
A 3-year randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy of alendronate therapy in preventing bone loss in healthy women who had recently experienced menopause.
Risk of hip fracture in women with vertebral fracture
TLDR
Data from a population‐based retrospective cohort study on Rochester women who were first diagnosed with one or more vertebral fractures in 1950–1979 are consistent with heterogeneity in the pathogenesis of different osteoporotic fractures.
Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy.
TLDR
It is hypothesized that the increased bone turnover in osteoporosis also is a major cause of vertebral fractures because of its adverse effects on the microarchitecture of the vertebrae and that normalization of bone turnover by antiresorptive drug therapy will decrease VFR substantially.
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
  • P. Garnero, E. Hausherr, +7 authors P. Delmas
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1996
TLDR
Elderly women are characterized by increased bone turnover, and some markers of bone resorption predict the subsequent risk of hip fracture independently of hip BMD, which may be useful to improve the assessment of the risk of Hip fracture in elderly women.
Prevalence of low femoral bone density in older U.S. women from NHANES III
  • A. Looker, C. Johnston, +5 authors R. Lindsay
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1995
TLDR
The first data on BMD from a nationally representative sample of older women show a substantial number with low femoral BMD, including the majority of white women but the number of minority women with low BMD is not trivial.
Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III
  • A. Looker, E. Orwoll, +6 authors S. Heyse
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1997
TLDR
Dual‐energy X‐ray absorptiometry measurements of femoral bone mineral density (BMD) from the third National Health and Nutrition Examination Survey (NHANES III, 1988–1994) are used to estimate the overall scope of the disease in the older U.S. population and explore different approaches for defining low BMD in older men in that age range.
...
1
2
3
4
...